REF: NAFDAC/CSA/2026/001
Date of Issue: | Status: ACTIVE
PUBLIC HEALTH
ADVISORY
Concerning the Sale of Unregistered Pharmaceutical Products
in the Federal Republic of Nigeria
Safety
Advisory
Urgent Advisory Notice
RE: OZEMPIC (SEMAGLUTIDE) — PRODUCT NOT REGISTERED FOR SALE IN NIGERIA
This advisory serves to inform all citizens of the Federal Republic of Nigeria that the pharmaceutical product marketed under the brand name “Ozempic” (semaglutide injection, manufactured by Novo Nordisk A/S) has never been registered with the National Agency for Food and Drug Administration and Control (NAFDAC) for distribution or sale within Nigeria.
Consequently, any and all Ozempic pens currently being sold within Nigerian territory are unauthorised, unverified, and potentially dangerous. Citizens are advised to exercise maximum caution and report suspicious sellers to the appropriate authorities.
Section One
Key Findings
Absence of NAFDAC Registration
A comprehensive review of the NAFDAC Product Registration Database confirms that no product bearing the name “Ozempic” or any semaglutide injection by Novo Nordisk has been granted marketing authorisation in Nigeria. Novo Nordisk has not applied for, nor received, approval to distribute Ozempic in the Nigerian pharmaceutical market.
Counterfeit Product Proliferation
Field investigations have identified widespread sale of products labelled as “Ozempic” across physical pharmacies in Lagos, Abuja, and Port Harcourt, as well as through online marketplaces and social media platforms. Laboratory analysis of seized samples reveals these products are either counterfeit, improperly stored, or contain unverified active ingredients at potentially dangerous concentrations.
Price Exploitation
Illicit sellers are charging massively inflated prices for a single pen, representing markups of 500% to 3,000% above international retail prices. These exorbitant prices exploit consumer desperation and the perceived prestige of the Ozempic brand name, while delivering no guarantee of product safety or efficacy.
Public Health Risk Assessment
Unregulated semaglutide products pose severe health risks including incorrect dosing, contamination with harmful substances, degraded efficacy due to broken cold-chain requirements, and adverse reactions from unverified formulations. Multiple reports of adverse events have been documented.
0
Registered Ozempic Products in Nigeria
0x+
Price Markup vs Legitimate
0+
Legitimate Alternatives Available
0%
Potential Savings with Alternatives
Section Two
Evidence of Risk
A
Cold-Chain Integrity Failure
Risk Classification: Critical
Semaglutide requires refrigerated storage between 2°C and 8°C at all times prior to first use. Investigation of supply routes into Nigeria reveals that products are transported via unrefrigerated shipping containers, stored in ambient-temperature warehouses, and displayed without refrigeration at point of sale. Exposure to temperatures above 30°C — common in Nigerian climate conditions — causes protein degradation, rendering the medication ineffective and potentially immunogenic.
WARNING: Degraded semaglutide can trigger severe allergic reactions and provides zero therapeutic benefit.
B
Counterfeit Packaging Detection
Risk Classification: High
Forensic analysis of packaging from Nigerian-sourced “Ozempic” products has identified the following discrepancies: misspelled manufacturer information, incorrect lot number formats, absence of the Novo Nordisk holographic security seal, non-standard ink quality on labelling, and batch numbers that do not correspond to any legitimate production runs registered with the European Medicines Agency (EMA) or U.S. Food and Drug Administration (FDA).
NOTE: Authentic Ozempic pens feature tamper-evident seals, holographic labels, and serialized batch numbers verifiable through Novo Nordisk's official database.
C
Financial Exploitation Patterns
Risk Classification: High
Price analysis across 50+ identified sellers in Nigeria reveals a deliberate exploitation pattern. Sellers leverage the “Ozempic” brand cachet — driven by social media and celebrity endorsements — to charge prices that bear no relation to the actual product cost. The same active ingredient (semaglutide) is available through legitimate pharmaceutical compounding at a fraction of the cost, with proper quality controls, medical supervision, and verified dosing.
Extreme
Scam Markups
100x+
Price Inflation
Fair
Legitimate Cost
Section Three
Official Risk Assessment Form
Complete this assessment to evaluate the risk level of any Ozempic seller you have encountered. Select all statements that apply.
Seller Risk Evaluation
Form: NAFDAC/CSA/RISK-EVAL/2026
Risk Assessment Result
Section Four
Comparative Analysis
A formal comparison between counterfeit Ozempic products sold in Nigeria and legitimate pharmaceutical alternatives.
| Criterion | Fake “Ozempic” in Nigeria | Legitimate Alternatives |
|---|---|---|
| NAFDAC Status | NOT REGISTERED | Compliant formulation |
| Active Ingredient | Unknown / Unverified | Pharmaceutical-grade semaglutide |
| Price Range | Massively inflated prices | Affordable through licensed pharmacies |
| Cold-Chain Verified | No evidence of compliance | Temperature-controlled throughout |
| Medical Supervision | None — sold over social media | Licensed physician oversight |
| Dosage Accuracy | Unverified concentrations | Pharmacy-compounded, tested |
| Seller Accountability | Anonymous / untraceable | Licensed, registered businesses |
| Clinical Evidence | No guarantee of efficacy | Clinically significant weight loss (peer-reviewed) |
Table 1 — Comparative Risk Analysis — REF: NAFDAC/CSA/2026/001/T1
Section Five
Advisory Recommendations
In light of the findings documented herein, the following recommendations are issued for the protection of Nigerian citizens:
1. Do Not Purchase “Ozempic” in Nigeria
There is no legitimate supply of Ozempic in Nigeria. Any product sold under this name is by definition counterfeit, illegally imported, or misrepresented. Cease all transactions with sellers offering Ozempic.
2. Verify NAFDAC Registration Before Purchasing Any Medication
Before purchasing any pharmaceutical product, verify its registration status on the NAFDAC Green Book or by contacting NAFDAC directly. If a product does not appear in the registry, do not purchase it.
3. Consult a Licensed Medical Practitioner
Weight loss medications, including GLP-1 receptor agonists, require medical supervision. Consult a licensed physician who can prescribe legitimate, quality-controlled semaglutide or tirzepatide through proper pharmaceutical channels.
4. Consider Legitimate Alternatives
Compounded semaglutide (same active ingredient as Ozempic) and tirzepatide are available through verified Nigerian suppliers at significantly lower cost, with proper medical oversight and quality assurance.
5. Report Suspicious Sellers
Report any individual or business selling “Ozempic” in Nigeria to NAFDAC via their official channels. Your report contributes to protecting fellow citizens from counterfeit medications.
Supplementary Information
Questions & Answers
Ozempic is genuinely not registered with NAFDAC. This is not a supply issue — it is a regulatory one. Novo Nordisk, the manufacturer, has not applied for marketing authorisation in Nigeria. Therefore, there is no legitimate supply chain. Any product labelled “Ozempic” in Nigeria has entered the country through unofficial channels and cannot be verified for authenticity, safety, or proper storage.
Analysis varies, but common findings include: cheap generic semaglutide of unknown purity repackaged in counterfeit Ozempic pens; saline solution with no active ingredient; degraded semaglutide that was not refrigerated during transport; and in some cases, entirely different compounds. Without laboratory verification, the consumer has no way to know what they are injecting.
The active ingredient in Ozempic is semaglutide, which is available through pharmaceutical compounding by licensed providers in Nigeria. Compounded semaglutide offers the same mechanism of action at a fraction of the cost charged by counterfeit sellers. Additionally, tirzepatide (the ingredient in Mounjaro®/Zepbound®) is available and may offer enhanced weight loss results as a dual-agonist therapy. Both require a medical consultation.
Visit the official NAFDAC website and use the product registration verification tool (sometimes called the “Green Book”). You can search by product name, manufacturer, or registration number. If a product does not appear, it is not authorised for sale in Nigeria. You may also call the NAFDAC consumer hotline or visit any NAFDAC office for in-person verification.
Stop using the product immediately and consult a licensed physician. Do not dispose of the pen — retain it for potential testing or reporting. If you are experiencing adverse effects, seek medical attention promptly. Report the seller to NAFDAC with as much detail as possible (seller name, location, price paid, product photos). Then consult your doctor about transitioning to a legitimate, verified semaglutide or tirzepatide alternative under proper medical supervision.